Skip to main content

Table 1 Sociodemographic and basic clinical data of the study population

From: Hepatitis B infection and risk factors among children living with HIV in Yaounde, Cameroon: an integrated management

Overall study participants 83 (100%)
CD4 cells count, cells/mm3, median [IQR] 1031 [830–1330]
VL
  < 50 21 (25.3%)
 50–999 13 (15.6%)
  ≥ 1000 15 (18.1%)
 Unknown viremia 34 (41%)
WHO clinical Stages, n(%)
 I 72 (86.7%)
 II 6 (07.2%)
 III 3 (3.6%)
 IV 2 (2.4%)
Gender, n(%)
 Male 38 (45.8%)
 Female 45 (54.2%)
Age (Year), Median [IQR[ 9 [6–12]
Preterm babies
 Yes 5 (6.0%)
 Non 78 (94.0%)
Feeding option
 Exclusive breastfeeding 24 (28.9%)
 Replacement feeding 18 (21.7%)
 Mixed feeding 41 (49.4%)
Infant anti-HBV vaccination status
 Yes 50 (60.3%)
 No 33 (39.7%)
Bath at birth
 Yes 21 (25.3%)
 No 62 (74.7%)
Maternal HAART during pregnancy
 TDF-3TC-EFV 64 (77.1%)
 Other regimens 13 (15.7%)
 ART-Naïve 6 (7.2%)
Maternal anti-HBV vaccination status during pregnancy
 Negative 08 (9.6%)
 Positive 01 (1.2%)
 Unknown 69 (83.1%)
 Vaccinated 05 (6.02%)
  1. ART antiretroviral therapy, HAART Highly Active Antiretroviral Therapy, HAART Highly Active Antiretroviral Therapy, HBV hepatitis B virus, IQR interquartile range, TDF-3TC-EFV tenofvoir-lamivudine-efavirenz, WHO World Health Organisation